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Psychological outcomes in persons with congenital adrenal hyperplasia (CAH) have received substantial attention. The
objectives of this paper were to (1) catalog psychological endpoints assessed in CAH outcome studies and (2) classify the
conceptual/theoretical model shaping the research design and interpretation of CAH-related psychological effects. A total of 98
original research studies, published between 1955 and 2009, were categorized based on psychological endpoints examined as
well as the research design and conceptual model guiding analysis and interpretation of data. The majority of studies (68%)
investigated endpoints related to psychosexual differentiation. The preponderance of studies (76%) examined a direct relationship
(i.e., inferring causality) between prenatal androgen exposure and psychological outcomes. Findings are discussed in relation to
the observed imbalance between theoretical interest in the role of prenatal androgens in shaping psychosexual differentiation and
a broader conceptual model that examines the role of other potential factors in mediating or moderating the influence of CAH
pathophysiology on psychological outcomes in both affected females and males. The latter approach offers to identify factors
amenable to clinical intervention that enhance both health and quality of life outcomes in CAH as well as other disorders of sex
development.
1. Introduction
Congenital adrenal hyperplasia (CAH) comprises a family of
autosomal recessive disorders involving impaired synthesis
of cortisol. In 21-hydroxylase deficiency (21-OH CAH),
the most common form comprising as many as 95% of
new cases, excessive adrenal androgen biosynthesis results
in masculinization of the genitals of 46, XX offspring [1].
Similar to other chronic pediatric conditions, CAH has
drawn the attention of clinical researchers interested in
the psychological sequelae of the condition and factors
contributing to variability in both physical health and quality
of life outcomes of affected persons.
Hormone replacement in CAH is imperfect and does
not mimic physiologic secretion. According to the 2002
Consensus Statement on 21-Hydroxylase Deficiency [2], the
goal of treatment is theminimization of adrenal sex hormone
and glucocorticoid excess, while simultaneously preventing
premature or inappropriate virilization, optimizing growth
and adult height, and preserving potential fertility. Because
of the masculinizing effects of prenatal androgen excess on
the genitalia, 21-OH CAH in 46, XX is now categorized as
a disorder of sex development (DSD) [3]. According to the
2006 Consensus Statement on the Management of Intersex,
DSD are “congenital conditions in which development of
chromosomal, gonadal, or anatomic sex is atypical” [3]
(p. e488). Both the CAH and DSD consensus statements
recognize the stress on patient and family associated with
a chronic life-threatening illness and, in the case of girls
and women affected with CAH, the added burden of
atypical genital anatomy. The DSD consensus statement also
notes that cultural and social factors modulate outcomes
in affected persons and, therefore, recommends that these
influences be taken into account in clinical care and research
design. The statement charges clinicians and researchers to
examine a wide range of psychological endpoints including
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“sexual function, and social and psychosexual adjustment,
mental health, quality of life, and social participation” [3] (p.
e493).
1.1. Psychological Endpoints in CAH. Much of what is
known about the psychological development of persons
affected with CAH (particularly females) stems from research
focused on elucidating the influence of atypical sex hor-
mone exposure during steroid-sensitive periods of brain
development [4–6]. Prenatal androgen excess associated with
masculinization of the genitalia is believed to influence the
development of regions of the brain responsible for sex
differences in behavior across a wide range of mammalian
species, including humans [7–9]. Accordingly, CAH has been
utilized as a model for testing hormonal hypotheses related
to the influence of early androgen exposure on behaviors
exhibiting sex-related variability, in particular psychosexual
differentiation (i.e., gender identity, gender role, and sexual
orientation) and sex differences in neurocognitive function.
Although the rate at which females with CAH experience
gender dysphoria is significantly higher than in the general
population, the large majority of females with CAH reared as
girls develop a feminine gender identity and do not express
feelings of gender dysphoria [10]. With regard to gender
role (i.e., behaviors that differ in frequency or level between
males and females that are promoted by social learning [11]),
affected girls prefer toys and activities characterized as male
typical [12, 13], are more likely to report the use of physical
aggression in conflict situations [14], and are less interested
in marriage, motherhood, and physical appearance [15] than
unaffected girls. In the case of sexual orientation, affected
women are more likely to have experienced homosexual
fantasies or behavior than their unaffected relatives [16,
17]. Consistent with theories regarding the role of early
androgens in the development of sex differences in cognitive
function, girls with CAH exhibit enhanced spatial reasoning
compared with unaffected siblings [18]. The apparent bias
toward utilizing CAH as a model to test hormonal theories
for the origins of sex differences in human behavior can be
inferred from the relative scarcity of psychological outcome
studies in CAH males. Affected males are of less interest in
this regard because prenatal androgen levels in males are
thought to fall within the normal range [19, 20] and because
gendered behavior of boys with CAH appears typical [8].
In contrast to extensive research on gender-related phe-
nomena, there has been relatively limited research addressing
psychosocial adaptation in either females or males. These
studies generally fail to show that CAH patients exhibit
an increased incidence of psychopathology relative to the
general population [21–23].
1.2. Conceptualization of the Effects of CAH on Psycho-
logical Outcomes. There are several ways to conceptualize
the influence of CAH on psychological endpoints [24,
25]. The simple or direct effect model involves a single
predictor (A) directly related to a single outcome (C). The
potential influence of other variables is not considered in
this model. An example of a direct effect model applied
to behavioral outcomes would be a study comparing the
sexual orientation of affected women to that of an unaf-
fected female control group. An increased frequency of
homosexuality or bisexuality has typically been attributed
to the influence of prenatal androgen exposure on brain
development [16, 17, 26]. Because other variables potentially
impacting the endpoint of sexual orientation have not been
formally examined or incorporated into the data-analytic
strategy, prenatal androgen exposure, by default, becomes
an appealing interpretation in light of animal experimental
research [6–8]. However, this simplest of conceptual models
does not reflect the view that sexual orientation in CAH
women is likely multifactorially determined [27].
When the relationship between predictor and outcome is
thought to be either buffered or intensified by another factor,
then a more suitable model than one depicting a direct effect
is one that tests for moderation. A moderator is a qualitative
(e.g., sex, form of CAH, salt wasting vs simple virilizing,
family’s ethnic background) or quantitative (e.g., age, serum
testosterone levels) variable that influences the direction
and/or strength of the relationship between predictor and
outcome variables. In other words, moderation occurs when
one variable affects the relationship between two other
variables such that the impact of the predictor (A) on the
outcome (C) varies according to the level or value of the
moderator (B). For example, gender assignment in 46, XX
CAH appears to be moderated by the country in which
the patient receives care. A comprehensive review of gender
assignment decisions in Western industrialized countries
shows that the vast majority of 46, XX CAH patients have
been reared as girls [10], while 46, XX CAH patients in more
patriarchal societies (e.g., Turkey) have a higher rate of male
gender assignment [28].
Finally, there aremediationmodels in which themediator
variable serves to clarify the nature of the relationship
between the predictor and outcome [25]. Rather than
hypothesizing a direct causal relationship between the pre-
dictor and outcome variables, a mediation model posits that
the predictor (A) influences another variable (B) which,
in turn, is more directly responsible for the outcome (C).
Potential examples of mediated effects of CAH on sexual
behavior include studies examining the outcomes of genital
surgery [29, 30]. In these reports, reduced genital sensitivity
and dissatisfaction or anxiety about genital appearance were
identified as factors accounting for decreased sexual activity
and pregnancy rates. The effect is not directly the conse-
quence of having CAH but is mediated through experiences
or consequences associated with its management.
Although incorporating a moderator or mediator in the
conceptual model helps sharpen our understanding of the
relationship between predictor and outcome, the researcher
must secure a larger sample size to ensure adequate statistical
power to demonstrate the influence of either [31, 32].
Because CAH is a relatively rare disease (1 in 15,000 births,
only half of whom are 46, XX), problems arising from the
larger sample size requirement may be remedied through
multicenter studies.
The objective of the current paper is two-fold: first,
to catalog studies of psychological endpoints assessed in
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CAH outcome studies and, second, to categorize these into
domains and subdomains. This objective’s importance flows
from the consensus statement on DSD [3] which drew
attention to the need to broaden the range of psychological
outcomes investigated and attended to in clinical care.
Second, it aims to classify the conceptual model (implicitly
or explicitly) applied to account for CAH-related effects on
psychological endpoints.
2. Materials and Methods
2.1. Study Eligibility Criteria. Original research studies pub-
lished in English between 1955 and 2009 were included in
this paper if study participants included persons affected
with 21-OH CAH (regardless of age or sex) and psycholog-
ical variables (broadly defined) were measured. Literature
reviews and research studies focusing on CAH pathophys-
iology that did not examine psychological endpoints were
excluded. Similarly, studies were excluded if data from
participants with varying medical diagnoses were combined
such that results for participants with CAH could not be
isolated.
Using the electronic databases OVID/Medline and
PsycINFO, searches were performed by combining terms
used to identify CAH with those likely to capture the
broadest possible range of psychological endpoints (See
Table 1). In OVID/Medline, the Medical Subject Heading
(MeSH) “Adrenal Hyperplasia, Congenital,” which encom-
passes “Adrenogenital Syndrome,” was combined with the
MeSH terms “Adjustment, Psychological” (capturing the
terms behavior, adaptive; coping behavior; adaptation,
psychologic; coping skills; psychological adaptation; psy-
chological adjustment), “Stress, Psychological” (comprising
anguish, emotional stress, life stress, mental suffering, and
suffering), and the terms of psychosexual development;
gender; gender identity; gender role; sexuality; sexual behav-
ior; sexual dysfunction; sexual dysfunction, psychological;
self-concept; body image; individual adjustment; quality
of life; fertility; conception; personality inventory; career
choice; religion; spirituality; psychopathology; mental dis-
orders; cognition; interpersonal relations; marriage; social
adjustment; social support; as well as results from the
combinations of family + psychology, family + attitude,
family + adjustment, and family + behavior. In the case of
searches performed on the PsycINFO database, the terms
“congenital adrenal hyperplasia,” “adrenogenital syndrome,”
and “intersex” were paired with the psychosocial terms listed
above. These procedures yielded a total of 98 articles.
2.2. Classification of Psychological Endpoints and Conceptual
Model. Two raters (SS and ML) used study summary forms
to reliably classify psychological endpoints assessed and
research design used in each study. Psychological endpoints
were classified into major domains and further divided
into subdomains to achieve greater specificity (Table 1).
Given that several studies examined multiple psychological
endpoints, the tabled numbers exceed the total number of
studies reviewed. Although most domain and subdomain
labels are self-explanatory, the Psychological Factors subdo-
mains warrant further explanation. Studies that employed
standardized measures based on diagnostic criteria of the
American Psychiatric Association Diagnostic and Statisti-
cal Manual [116] were categorized within the subdomain
Psychopathology. Those studies examining behavioral and
emotional symptoms, apart from diagnosable syndromes,
were categorized as Behavioral/Emotional Functioning.With
regard to the endpoint Health-Related Quality of Life,
only those studies which utilized questionnaires designed
specifically to assess this construct [117] were classified
in this subdomain. Reproduction comprised two subdo-
mains: studies which provided documentation of either the
frequency of pregnancy or frequency with which CAH-
affected women carried the pregnancy to term were classified
under Conception; all other measured outcomes dealing
with reproductive function were classified under Fertility
Status. Studies examining psychological factors that could
not reliably be classified within another domain/subdomain
were listed as “Other.” Examples of outcomes falling into
this category included parental attitudes toward gender
assignment [33, 34] or reactions to genital anomalies [28].
Reviewers also categorized studies based on their inter-
pretation of the underlying conceptual model guiding study
design and data analysis; that is, direct, mediated, or
moderated. This aspect of the paper was complicated by the
fact that investigators neither specified nor formally tested
the fit of specific conceptual models according to accepted
statistical practice (e.g., [24, 25, 32]) leaving it to the raters to
infer the type of model guiding the research. Disagreements
between raters were resolved by consensus involving the
senior author (DES).
Finally, studies were also categorized as employing quan-
titative, qualitative, or mixed-methods (i.e., involving a com-
bination of both quantitative and qualitative methodologies)
[118] approaches. Quantitative research primarily uses a
deductive process to test prespecified concepts, constructs,
and hypotheses that make up a theory. The aim is to classify
features, count them, and construct statistical models in
an attempt to explain observed phenomena. In contrast,
qualitative research primarily uses an inductive process to
formulate theory. Qualitative research methods commonly
involve detailed analysis of data such as transcripts from
interviews. This approach is fundamentally more subjective,
for example, by describing a problem or condition from the
point of view of those experiencing it [119].
3. Results
3.1. Classification of Psychological Endpoints. Of the 98
articles reviewed, 67 (68%) studied endpoints were classified
in the Psychosexual Differentiation domain. The majority
within this domain included an assessment of Gender Role
(n = 46, 46%), followed by Gender Identity (n = 27, 27%)
and Sexual Orientation (n = 28, 29%) (Table 1). The next
most frequently investigated endpoints were categorized in
the domain of Psychological Factors (n = 28 studies, 29%).
The remaining domains and subdomains are summarized
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Table 1: Classification of psychological endpoints by domain and subdomain†.
Domain (# Studies) Subdomain (# Studies) References
Psychosexual Differentiation (67)
Gender role (46)
[4, 5, 12–17, 22, 26, 28, 33–88]Gender identity (27)
Sexual orientation (27)
Psychological Factors (30)
Self-concept (18)
[5, 21–23, 28, 30, 33, 40–
42, 49, 51, 55, 57, 65, 69, 71, 72, 74, 81, 86, 87, 89–96]
Behavioral/emotional
functioning (11)
Psychopathology (10)
Health-related quality of life (5)
Sexuality (25)
Sexual function (2) [16, 26, 29, 30, 38, 40, 41, 43, 50, 52, 65, 69–72, 81–
84, 87, 89, 97–100]Sexual activity (17)
Social Adaptation (25)
Social functioning (12) [14, 17, 21, 23, 38, 40, 41, 46, 52, 55, 56, 69–
72, 81, 82, 84, 87, 89, 90, 93, 97, 98, 100]Cohabitation/marriage (15)
Cognitive Function (23) [4, 28, 35, 48, 53, 55, 57, 64, 67, 98, 101–113]
Reproduction (10)
Fertility status (7)
[40, 50, 52, 70, 85, 87, 89, 94, 114, 115]
Conception (8)
Other (8) [28, 33, 34, 40, 71, 82, 87, 89]
Education/Occupation (7) [51, 65–67, 87, 92, 100]
†
Individual studies examined multiple endpoints; numbers of studies within domain/subdomain therefore exceed the total number of studies reviewed (N =
98).
in Table 1. Studies employing quantitative methods alone
comprised 76% of the reviewed literature, 18% were classi-
fied as qualitative, and 6% were applied to a combination of
quantitative and qualitative strategies, that is, mixedmethods
(not shown in Table).
3.2. Classification of Conceptual Models. Seventy three of 98
studies (74%) interpreted the psychological outcome as a
direct consequence of CAH pathophysiology (Table 2). For
example, masculinized gender-role behavior and neurocog-
nitive profiles in affected girls are commonly explained in
terms of a direct effect of excess prenatal androgen exposure
on brain development in affected girls (e.g., [35, 36, 101]).
The majority of studies within the domains of Psychosexual
Differentiation (57 of 67), Psychological Factors (21of 30),
Cognitive Function (22 of 23), Social Adaptation (19 of 25),
Sexuality (13 of 25), Reproduction (8 of 10), and all studies
examining Education/Occupation (7) endpoints applied a
direct effect conceptual model.
A minority of reviewed studies (15 of 98, 15%) examined
the possibility that a third variable moderated the asso-
ciation between CAH and the outcome variable. Studies
which adopted this approach targeted endpoints classified
as Psychosexual Differentiation (8), Cognition (6), Sexuality
(2), Psychological Factors (2), and Social Adaptation (2).
For example, Berenbaum [37] demonstrated that effects of
CAH on sex-typed play activities and interests were restricted
to affected girls. The statistical interaction between sex of
patient and type of play and interests constitutes evidence of
a moderating variable. Across all studies, the moderator vari-
able most frequently considered was participant’s biological
sex (13 of 15, 87%) (Table 2).
A slightly higher proportion of studies (29 of 98, 30%)
adopted a mediation model (i.e., consideration that all or
a portion of the influence of CAH on the outcome was
mediated through another variable). Studies attending to the
possibility of mediated effects tracked endpoints in the fol-
lowing domains: Psychosexual Differentiation (18), Sexuality
(11), Psychological Factors (7), Social Adaptation (5), Other
(4 articles examining family response to CAH and deepness
of voice), Reproduction (3), and Cognition (1). For example,
Zucker and colleagues [38] reported that for both women
with CAH and their unaffected relatives, higher self-reported
sexual arousability positively predicted relationship status,
level of sexual attraction to men in fantasy, greater likelihood
of heterosexual behavior, and more sexual experiences with
men. The only statistically significant predictor of sexual
arousability (for both CAH women and unaffected relatives)
was lifetime sexual experiences with men. In other words,
what differentiated CAH and healthy womenwas the amount
of sexual experience by the time of study participation,
whether or not they had CAH. Accordingly, if control
group participants for any reason had more limited sexual
experience, then they also would have been expected to
show reduced sexual arousability. In this context, “sexual
experience” is conceptualized as mediating the influence of
CAH on sexual arousability.
Other examples of studies allowing for mediated effects
included Hall et al. [39] and Slijper [88]; both introduced a
control group comprised of comparably-aged patients with
diabetes to control for “very similar life experiences that
accompany their respective chronic illnesses: regular outpa-
tient attendances, daily medication, decompensation during
intercurrent illnesses, potentially life-threatening crises, and
adverse impact on family life, schooling, and social life” [39].
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Table 2: Summary of conceptual models applied to study of psychological endpoints†.
Conceptual Model Number of Studies References
Direct Effect 73
[4, 5, 12–17, 21–23, 26, 28, 35, 36, 38, 40–42, 44, 46–48, 50, 51, 53–
56, 58–61, 64–70, 72–80, 83, 84, 86, 87, 89, 90, 92–
94, 97, 98, 100, 101, 103–107, 110–115]
Mediating 29
[16, 30, 33, 34, 38–40, 43–45, 49, 50, 52, 56, 57, 62, 63, 71, 74, 80–
82, 85, 88, 91, 95, 96, 99, 102]
Moderating 15 [4, 5, 12, 29, 37, 53, 54, 58, 75, 89, 93, 103, 108, 109, 111]
†
Individual studies examined multiple endpoints; numbers of studies within domain/subdomain therefore exceed the total number of studies reviewed (N =
98).
A total of 7 of 98 studies (7%) incorporated a control group
comprised of chronically ill participants.
4. Discussion
One objective of this paper was to catalog studies of CAH
which included psychological endpoints. A total of 98
original studies published between 1955 and 2009 formed
the dataset for our analysis. The majority of investigations
(68% of total) examined endpoints related to psychosexual
differentiation (i.e., gender identity, gender role, or sexual
orientation). Classic 21-OH in females has long served as
a human model for the study of early androgen exposure
effects on the developing brain. This focus accounts for
the fact that affected males, assumed to be exposed to
a relatively typical prenatal androgen milieu [19, 20], are
underrepresented in CAH psychological outcome studies.
A number of potential problems emerge as a consequence
of this arguably unbalanced research portfolio. For example,
there is the risk that the emphasis on gender-role behavior
in girls and women may be misinterpreted by consumers of
this research (including healthcare providers, patients, and
their families) as gender-atypical behavior being a significant
source of concern rather than an observation primarily of
theoretical importance [120]. Recent reports in the lay media
[121–123], as well as an essay published on an authoritative
bioethics website [120], suggest that this risk is, in fact,
real. At the center of the current controversy is the practice
of prescribing dexamethasone (dex) to pregnant women at
risk for carrying a female fetus with CAH. Prenatal dex
has been shown to diminish the degree of masculinization
of female genitalia which may obviate the perceived need
for genital surgery [124]. Research findings reported at a
recent conference [125] suggest that this same treatment is
associated with a similar reduction in the masculinization
of behavior. The media and bioethicists interpreted interest
in the gender outcome as indicating that the investigators
believed that the gender behavior of these girls is a legitimate
target for clinical intervention.
An overemphasis on gender-related outcomes has also
been associated with a relative scarcity of studies investigat-
ing endpoints that relate more directly to improving clinical
care. Previous work suggests that both the physical sequelae
of the condition and modulation of circulating corticos-
teroids can affect psychological outcomes. For example, stud-
ies examining the influence of hirsutism, acne, short stature,
or deep voice [87] on outcomes such as body image [40]
provide information of potentially great relevance to clinical
care, but such studies are relatively scarce. Furthermore,
little attention is directed towards the effects of suboptimal
hormone replacement therapy on emotional reactivity in
male and female CAH patients. Studies have consistently
found dysregulation of the hypothalamic-pituitary-adrenal
(HPA) axis, particularly increases in corticotropin-releasing
hormone (CRH), to be related to symptoms of depression,
anxiety, panic, and posttraumatic stress disorder [126]. Sim-
ilarly, relatively little consideration has been given to the fact
that adrenal medulla function is also compromised in 21-
OH CAH, resulting in decreased production of epinephrine.
Plasma epinephrine and metanephrine concentrations are
substantially lower in patients with CAH than in unaffected
individuals, especially in those individuals who had been
hospitalized for adrenal crisis [127]. Although apparently
not life threatening, this deficiency may result in decreased
endurance during long-term physical stress [128, 129]. This
aspect of adrenal function clearly warrants further study
because of implications not only for the physical health of the
CAH-affected person but also for their health-related quality
of life.
In addition to the restricted focus on endocrine abnor-
malities in CAH as predictors of outcomes, relatively little
consideration has been given to social contextual factors
(e.g., ethnic, religious, or familial environments [28]) in
which intuition and a large body of evidence from the pedi-
atric psychology literature [130, 131] suggest exerting strong
and lasting effects on the development of children. In the case
of CAH, factors to consider include family adaptation to the
birth and parenting of a child with a rare life-threatening
chronic illness, decision-making regarding genital surgery
in girls and its timing and possible decisional regret, to
name only a few. Our review also revealed that relatively
little attention has been directed toward constructs that may
exert profound and lasting effects on the persons and their
social relationships; examples include the development of
a distorted body image and feelings of shame and fear of
disclosure of medical information [30, 41, 42, 89]. This
gap in theory-driven research makes it difficult to develop
evidence-based psychosocial interventions to prevent or
ameliorate predictable negative sequelae of CAH at different
stages of development. Progress in this respect will be greatly
facilitated through the development of health-related quality
of life questionnaires that focus on issues specific to and
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shared by patients with CAH and other disorders of sex
development and their families, which are not otherwise
covered by generic health-related quality of life measures
[132].
The second objective of this paper was to character-
ize the conceptual/theoretical models guiding individual
studies. For many, the underlying conceptual model had
to be inferred from the selection of control/comparison
groups, the statistical analysis employed, or through the
investigators’ interpretation of the data. The majority of
studies implicitly or explicitly posited a direct effect of
prenatal CAH pathophysiology (i.e., elevated androgens) on
the developing brain, and this tendency was most notable
for studies examining gender-role behavior and cognitive
function. However, even in the case of other psychosexual
endpoints, where the evidence for organizational effects of
prenatal androgens on the developing brain (i.e., gender
identity and sexual orientation) has not been established,
investigators rarely articulated (let alone statistically tested)
for moderating or mediated effects. Instead, data analysis
and interpretation suggested that the investigators assumed
a causal rather than correlational relationship between CAH
hormonal abnormalities and psychological outcomes.
The current paper also showed that the majority of
studies (76%) were quantitative, employing standardized
measures to assess behavior in predetermined domains. Rel-
atively few studies employed qualitative or mixed methods.
Findings from several of these suggest the promise of this
approach in identifying areas of particular relevance to
clinical care. A poignant example comes from a qualitative
study byMay and colleagues [43]. It was reported that a lower
percentage of women with CAH masturbated compared
with women in a diabetes control group. Explanations given
by CAH participants were illuminating. One participant
described masturbation as a necessary medical procedure
rather than one performed for sexual pleasure: “ [mas-
turbation was necessary] to keep it [the vagina] open. I
have done so, everybody does, I used to have to, I would
explore-what had [the surgeons] done? Even now, I’ve never
thought about it for enjoyment” (p.484). Regardless of the
generalizability of this observation, it suggests a direction for
investigations examining the effects of medical examinations
and procedures that may influence sexual experiences. In the
same way, knowledge of patient subjective experiences such
as these can directly inform the model of clinical care, for
example, referral for sex therapy [3].
An implication of this paper is the need for larger sample
sizes in order to test moderated and mediated models of
CAH effects with adequate statistical power. Because CAH
is a rare disease, the development of multisite collaborations
is essential to progress. An example of such collaboration
is Euro DSD, a consortium supported by the European
Union [133]. As already noted, a broadened research agenda
that includes assessment of psychological outcomes directly
relevant to patients’ lives will hopefully spur efforts in the
development of well-informed psychosocial interventions.
Finally, two aspects of the methodology of this paper
should be kept in mind: first, there is a possibility that
some eligible studies were missed despite our best efforts
to be complete. Because studies were identified using both
Medline and PsychINFO databases, we do not believe that
the addition of missed articles would fundamentally alter any
of our findings or conclusions. Accuracy in categorization
of studies according to the underlying conceptual model is
more problematic. We made every effort to seek reliability
in the process but expect that others, attempting the same
task, might generate a somewhat different result than that
summarized in Table 2. Here also, we do not expect that a
reclassification of individual studies will fundamentally alter
the conclusion that the majority of research on psycholog-
ical endpoints in CAH arises from a direct effect model.
Nonetheless, it should be noted that studies published in
this special issue, but beyond the cutoff year for this paper
(2009), hint at increased interest in the use of qualitative
methods and examination of family contextual variables
(e.g., [134, 135]).
This paper will hopefully serve to encourage investigators
to design new studies that attempt to model some degree
of the complexity of the lives of children, adolescents, and
adults (both women and men) with CAH and their families.
Such approaches are firmly established in other areas of
health research [136]. Because the theoretical framework for
studying psychological outcomes of persons with DSD other
than CAH is similarly focused on the putative action of
androgens on sex-dimorphic brain development and psycho-
sexual differentiation [137–139], it is perhaps obvious, but
nonetheless worth mentioning, that all that has been stated
in this paper regarding the CAH research agenda potentially
applies to all other conditions currently categorized as DSD.
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